Introduction
Plasmodium falciparum is the parasite responsible for the most severe and deadly form of human malaria, a mosquito-transmitted disease that affects millions of people every year particularly in tropical and subtropical climates. Metabolically stable analogues of the natural product artemisinin are currently the most effective agents for the treatment of malaria, and their use in combination therapies are recommended for the treatment of P. falciparum infections in areas where there is a widespread resistance to other existing drugs. However, the emergence and recent spread of artemisinin-resistant parasites, first identified in Southeast Asia, represent a major threat to human health that jeopardises the current fight to control malaria, and urges the development of new high-efficacy antimalarials [1] .
The proteasome is a large protease complex essential in all eukaryotes. It comprises a 20S core formed by four hetero-heptameric rings of a and b subunits stacked into a dimeric a 7 b 7 b 7 a 7 barrel-shaped assembly. The active sites of the proteolytic active subunits, b1, b2 and b5, are located within its inner chamber (Fig. 1) . The organisation of this assembly is well established, with the first structures of 20S proteasomes determined by X-ray crystallography nearly 20 years ago [2, 3] . Apart from its role in general proteostasis, the proteasome is responsible for the highly regulated degradation of proteins, the removal of which coordinates fundamental processes such as cell cycle progression [4] . While the 20S proteasome is a well-established target for cancer therapy [5] , its inhibition is being explored as a therapeutic approach for a wider range of conditions including inflammatory disorders [6] , viral infections [7] and tuberculosis [8] .
The initial observation that inhibition of the Plasmodium proteasome is toxic for the parasite [9] , and the subsequent demonstration that it has distinct ligand-binding preferences to the human complex [10] [11] [12] suggest the parasite proteasome as a suitable target for the development of a new class of antimalarials. Furthermore, recent data revealed that inhibition of the Plasmodium proteasome has synergistic activity with front-line artemisinin-based drugs, and that the unfolded protein response (UPR), which is a proteasome-mediated stress response pathway, is upregulated in Plasmodium field isolates from Southeast Asia that have a delayed response to those drugs [13] . Thus, inhibitors of the proteasome not only have the potential to kill parasites through disruption of cell cycle and other critical processes but they may also help to prevent the induction of resistance to artemisininbased and other antimalarial drugs that induce a UPR response.
When exploring proteasome inhibitors as antimalarials, the ability to obtain a high degree of ligand specificity for the Plasmodium proteasome over the human host complex is paramount to prevent toxicity of any lead molecules. Thus, the characterisation of the parasite 20S proteasome at a molecular level is important to rationalise differences between the parasite and human proteasome ligand-binding preferences that can be exploited for drug development efforts [14] . We achieved this goal in a collaborative effort [15] , which included determining the structure of the P. falciparum 20S proteasome bound to a new parasite-specific inhibitor by electron cryo-microscopy (cryo-EM) and single particle analysis. This structure, at a resolution of about 3.6 A, when compared with its human counterpart, revealed the molecular basis for the specific ligand binding to the parasite complex. The new structure can further assist in the design and improvement of proteasome inhibitors with credible therapeutic potential against malaria, directly highlighting the impact of the fast evolving field of high-resolution cryo-EM on the rational development of therapeutic drugs. A rational strategy to define the specificity of the P. falciparum active sites
The identification of ligands suitable for drug development frequently relies on brute force high-throughput screening of the target protein against large libraries of ligands, and the structural characterisation of the subsequent protein-ligand interactions for positive hits usually by X-ray crystallography. This approach requires the direct determination of the protein structure in the presence of candidate ligands or, if the structure of the protein binding pocket is known, the computational modelling of protein-ligand interactions followed by validation by structure determination. A screening of noncovalent ligands previously showed that the P. falciparum and human proteasomes have distinct ligand-binding preferences [11] , but without knowledge of the molecular basis for such specificity, the prospects for drug development were limited. In a major step-forward to further characterise these specific ligand-binding preferences, we determined cleavage site amino acid frequency profiles of P. falciparum and human proteasomes against a library of diverse peptide substrates [15] , and found an unusual preference of the parasite complex for tryptophan residues at the substrate positions P1 and P3 (Fig. 2) . Using this information, we prepared peptide-vinyl sulfone prototype inhibitors (WLL-vs, WLW-vs and LLW-vs, Fig. 2 ) that act by covalently modifying the Thr1 residue of the proteasome catalytic subunits [16] , and tested them in biochemical and cell biological assays to characterise their interactions to each of the individual P. falciparum and human proteasome active sites [15] . We identified WLW-vs as having the highest specificity towards the parasite complex, binding exclusively at its b2 active site. A high-resolution structure of the P. falciparum 20S proteasome/inhibitor complex was then required to fully describe the molecular basis for this high degree of specificity.
Determining the structure of the WLW-vs-bound P. falciparum 20S proteasome X-ray crystallography has been extensively used to study the interactions of yeast and mammalian 20S proteasomes with ligands in order to assist drug development [17, 18] , but for these studies, the protein sample must be amenable to crystallisation. While there are well-established protocols for the preparation of highly pure yeast and mammalian 20S proteasomes in quantities and concentrations suitable for crystallography, the preparation of such samples directly from P. falciparum cultures is not practical due to the small yield of proteasomes obtained. On the other hand, the recent revolution in the field of structural cryo-EM has made it a suitable method to determine protein structures at resolutions that used to be achievable only by X-ray crystallography or NMR [19] . Archaeal proteasomes have been used as a test sample for cryo-EM imaging conditions and image processing methods, resulting in structures at resolutions as high as 2.8 A [20, 21] . However, these are not suitable models to infer detailed ligand selectivity properties of the active sites of eukaryotic proteasomes, which are functionally and structurally more complex.
We recently used human 20S proteasome samples to demonstrate that cryo-EM and single particle analysis can be used to determine the structure of eukaryotic proteasomes at resolutions that show the conformation of side chains of peptide-derived ligands bound to the active sites [22] . This analysis also highlighted the significant advantages of using cryo-EM for the study of proteasome-ligand interactions, including using conditions that more closely resemble a physiological environment and preserve the subunit ligand-binding specificity patterns. In contrast, analysis by X-ray crystallography normally requires either protein cocrystallisation, or the soaking of protein crystals with excess of ligand. In either case, the protein environment is optimised to facilitate crystallisation, and the exposure to excess ligand under such conditions, together with possible active site access modulation due to crystallographic constraints, can greatly alter the physiological binding selectivity of a molecule. Most importantly, the significantly smaller amounts of purified protein required for cryo-EM methods makes existing preparations of P. falciparum 20S proteasomes adequate for high-resolution structure analysis. Using the same strategy as for the cryo-EM analysis of the human proteasome [22] , we determined the cryo-EM structure of the P. falciparum 20S proteasome bound to WLW-vs at a resolution of 3.6 A (Electron Microscopy Data Bank entry EMDB-3231, Protein Data Bank accession number 5FMG, Fig. 1 ) [15] . Densities for the ligand were clearly recovered extending from the proteolytic active Thr1 residue of only the b2 subunit (Fig. 3) , thus validating the observed occupancy from the in vitro inhibition studies.
Structural basis for the P. falciparum 20S proteasome ligand-binding specificity Our structure of the P. falciparum 20S proteasome shows that the WLW-vs bound at the b2 subunit active site takes a nearly planar beta secondary structure conformation, analogous to that of other peptidederived inhibitors bound to yeast or mammalian proteasomes [14] . The ligand morpholine, leucine side chain and vinyl sulfone groups are oriented towards the solvent-filled inner cavity of the complex, while the tryptophan side chains at positions P1 and P3 face the protein surface (Fig. 3) . Accordingly, our structure shows that the selective binding of WLW-vs arises from the uniquely open Plasmodium b2 ligandbinding pocket, which can accommodate tryptophan side chains at positions P1 and P3, while the human complex cannot (Fig. 4) . Furthermore, our structure also shows that this is the only binding site, among all of those from the human and parasite proteasomes, compatible with such bulky side chain at the P1 position, providing the basis for the WLW-vs specificity [15] .
While WLW-vs is the most specific of the new prototype ligands tested, the exclusive inhibition of the parasite proteasome b2 active site is not sufficiently toxic to kill the parasite [12] . Nevertheless, in vivo assays showed that WLW-vs successfully synergises with dihydroartemisinin to kill artemisinin-resistant parasites, suggesting a potential therapeutic usage of WLW-vs derivatives in combination therapy with artemisinin-based compounds. On the other hand, our structure indicates that a tryptophan at the P3 position can be accommodated by both the parasite b2 and b5 sites. The simultaneous inhibition of these two sites results in significantly enhanced toxicity for the parasite, as we demonstrated in vitro and in vivo (in P. falciparum cultures) using the ligand WLL-vs [15] . Remarkably, a single dose of WLL-vs was sufficient to reduce the parasite to close to undetectable levels in a While the P1 and P3 side chains are well accommodated in the parasite b2-binding pocket (A, C), steric constraints limit accessibility to the human b2-binding pocket (B, D), which is occupied only at higher ligand concentrations where specificity is lost. Equivalent restrictions are observed for the b1-and b5-binding pockets of the parasite and human proteasomes [15] .
malaria mouse model, without apparent toxicity to the host. WLL-vs is therefore a suitable foundation for the development of new, highly potent and specific P. falciparum proteasome inhibitors as antimalarials.
Final remarks
While the proteasome is conserved among all eukaryotes, we showed that sufficient structural differences exist in complexes from different species to allow their specific targeting. While our study focused on the P. falciparum proteasome as an antimalarial target, it strongly suggests that a similar strategy may be applicable against other disease-causing protozoan parasites, including Trypanosoma, Leishmania, Toxoplasma and Entamoeba. In all these cases, high-resolution cryo-EM is likely to be the method of choice to obtain the structural information required to guide drug design. Finally, cryo-EM does not yet provide the high-throughput structural data attainable by X-ray crystallography, which when using favourable proteins allows a fast, direct screening of their binding with candidate ligands. However, our results emphasise that structures determined by cryo-EM can provide information highly suitable for drug development, with the significant advantage of preserving ligand specificity. Furthermore, ongoing developments in cryo-EM instrumentation and data analysis are expected to yield consistently higher resolution structures, at a higher throughput. Such prospects, together with the already applicable advantages of using cryo-EM in the structural analysis of protein-ligand interactions, as we have shown, makes it foreseeable that in the near future cryo-EM may become the primary method of choice for such studies.
